In particular, the aims of our study were: i) to investigate whether PBMCs from patients affected by HL and B-cell NHL contain an increased percentage of CD66b+CD33dimHLA-DR− cells [16] as compared to healthy donors; ii) to characterize in detail the immunophenotypical features of the CD66b+CD33dimHLA-DR− cells; iii) to prove their immunosuppressive functions; iv) to evaluate eventual correlations between the percentage of CD66b+CD33dimHLA-DR− cells and the clinicopathological features, prognostic index scores, disease status, as well as outcome, of patients affected by HL and B-cell NHL. This evidence concerns the gene CEACAM8 and B-cell non-Hodgkin lymphoma.